Gilead (GILD) Partners With Eisai For RA Candidate In Japan
Zacks Investment Research | Dec 25, 2019 10:26PM ET
Gilead Sciences, Inc. (NASDAQ:GILD) announced that it has entered into an agreement with Eisai Co., Ltd for the distribution and co-promotion of its investigational, oral, selective JAK1 inhibitor, filgotinib, in Japan. The deal is pending approval.
The candidate is being evaluated for the treatment of rheumatoid arthritis (RA).
Per the terms of the deal, Gilead Japan will retain the responsibility of manufacturing and marketing approval of filgotinib, while Eisai will be in charge of product distribution in Japan in RA and other potential future indications. Both the companies will jointly commercialize the drug, if approved.
We note that filgotinib demonstrated durable efficacy and safety results across multiple RA patient populations. This includes patients with prior inadequate response to methotrexate treatment (MTX), those who were intolerant to one or more biologic treatments and those who were MTX treatment-naïve in phase III FINCH studies.
Per estimates, approximately 600,000 to 1 million patients are living with RA across Japan.
Earlier in the month, Gilead submitted a New Drug Application (NDA) for filgotinib to the FDA. A priority review voucher was submitted with the NDA, which will shorten the anticipated time for review.
Gilead and partner Galapagos NV (NASDAQ:GLPG) already have a global collaboration for the development and commercialization of filgotinib in inflammatory indications.
Global studies investigating filgotinib in additional indications are also underway, including the phase III SELECTION study in ulcerative colitis, the DIVERSITY phase III study in Crohn’s disease, the phase III PENGUIN studies in psoriatic arthritis and phase II studies in uveitis and in small bowel and fistulizing Crohn’s disease.
The European Medicines Agency has also accepted the marketing authorization application for filgotinib as a treatment for RA.
Gilead’s stock has gained 6.6% in the year so far compared with the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.